2014 Nomura Biotechnology Conference on November 6th
2014 Stifel Nicolaus Healthcare Conference on November 19th
BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 31, 2014--
Ocular Therapeutix (NASDAQ: OCUL), a biopharmaceutical company focused
on the development and commercialization of innovative therapies for
diseases and conditions of the eye, today announced that Amar Sawhney,
Ph.D., President and Chief Executive Officer, will be presenting at two
upcoming investor conferences:
2014 Nomura Biotechnology Conference
Thursday, November 6, 2014, at
10:00 a.m. Eastern Time
Mandarin Oriental Hotel, Boston,
Massachusetts
Panel: From Successful IPOs to Clinical Success: A
Focus on New Crop of Companies Focused on Disorders of the Eye
2014 Stifel Nicolaus Healthcare Conference
Wednesday, November 19,
2014, at 3:00 p.m. Eastern Time
The New York Palace, New York, New
York
Details of the webcast and a copy of the investor presentation
will also be made available in the Investor section of the Corporate
website at investors.ocutx.com.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
development and commercialization of innovative therapies for diseases
and conditions of the eye using its proprietary hydrogel platform
technology. Ocular Therapeutix’s lead product candidates are in Phase 3
clinical development for post-surgical ocular inflammation and pain, and
Phase 2 clinical development for glaucoma and allergic conjunctivitis.
The Company is also evaluating sustained-release injectable anti-VEGF
drug depots for back-of-the-eye diseases. Ocular Therapeutix’s first
product, ReSure® Sealant, is FDA-approved to seal corneal incisions
following cataract surgery.
Source: Ocular Therapeutix
Investors:
Ocular Therapeutix, Inc.
Brad Smith
Chief
Financial Officer
bsmith@ocutx.com
or
Burns
McClellan on behalf of Ocular Therapeutix
Kimberly Minarovich,
212-213-0006
kminarovich@burnsmc.com
or
Media:
Scott
Corning
Vice President of Sales and Marketing
scorning@ocutx.com
